This study is in progress, not accepting new patients

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

a study on Chronic Lymphocytic Leukemia Leukemia Acute Myeloid Leukemia Multiple Myeloma Lymphoma Non-Hodgkin Lymphoma Acute Lymphoblastic Leukemia Cancer, General Neoplasms

Summary

Location
at Los Angeles 5368361, California 5332921 and other locations
Dates
study started
study ends around

Description

Summary

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.

Keywords

Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer, Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Venetoclax, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Non-Hodgkin Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms

Eligibility

You can join if…

  • Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug.
  • Male subject agrees to refrain from sperm donation.
  • Female subjects must not be pregnant or breastfeeding.

You CAN'T join if...

  • None.

Locations

  • UCLA Santa Monica Hematology Oncology /ID# 210551
    Los Angeles 5368361 California 5332921 90095 United States
  • University of Arizona Cancer Center - Tucson /ID# 210548
    Tucson 5318313 Arizona 5551752 85724 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
Links
Related Info
ID
NCT03844048
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 165 people participating
Last Updated